Bretthauer Michael, Ahmed Jabed, Antonelli Giulio, Beaumont Hanneke, Beg Sabina, Benson Ariel, Bisschops Raf, De Cristofaro Elena, Gibbons Eimear, Häfner Michael, Karsenti David, Laquière Arthur, Loly Jean-Philippe, O'Reilly Susanne M, Pellisé Maria, Grubelic Ravic Katja, Triantafyllou Konstantinos, Tziatzios Georgios, Valente Roberto, Walter Benjamin M, Wiesand Malina, Lorenzo-Zúñiga Vicente, Gralnek Ian Mark
Clinical Effectiveness Research Group, Institute of Clinical Medicine, University of Oslo, and Department of Transplantation Medicine, Oslo University Hospital, Oslo, Oslo, Norway.
Imperial College Healthcare NHS Trust, London, UK.
Endoscopy. 2025 Jun;57(6):667-673. doi: 10.1055/a-2543-0370. Epub 2025 Mar 27.
This statement conveys the European Society of Gastrointestinal Endoscopy (ESGE) position on the use of computer-aided detection (CADe) with artificial intelligence (AI) during colonoscopy for colorectal cancer (CRC) screening or surveillance. The ESGE position is informed by the BMJ Rapid Recommendation initiative and the approach of the MAGIC Evidence Ecosystem Foundation; these include systematic reviews of currently available evidence, supplemented by microsimulation modeling and patient values and preferences, for the benefits and harms of AI CADe devices during colonoscopy.ESGE convened a panel of European experts for this Position Statement. On December 18, 2024, panel members voted on their preferred recommendation between two choices about CADe during colonoscopy for indications of CRC screening or polyp surveillance. Out of 19 eligible votes, 13 (68.4%) voted to recommend CADe for colonoscopy, and six panel members (31.6%) voted against. Therefore, the current ESGE statement is: RECOMMENDATION: The panel believes that most well-informed patients who have already decided to undergo colonoscopy for screening or surveillance would favor CADe assistance during colonoscopy. This is due to the potential benefits, although limited, of reduction in colorectal cancer incidence and mortality.This recommendation is weak, because the evidence is limited with considerable uncertainty of the evidence estimates, the absolute benefits for colorectal cancer incidence and mortality are small, and there is a patient burden associated with CADe (more polyp overdiagnosis and more colonoscopy surveillance).
本声明传达了欧洲胃肠内镜学会(ESGE)关于在结肠镜检查中使用人工智能(AI)辅助检测(CADe)进行结直肠癌(CRC)筛查或监测的立场。ESGE的立场是基于《英国医学杂志》快速推荐倡议以及MAGIC证据生态系统基金会的方法制定的;这些方法包括对现有证据进行系统综述,并辅以微观模拟建模以及患者价值观和偏好,以评估结肠镜检查期间AI CADe设备的利弊。ESGE为此立场声明召集了一个欧洲专家小组。2024年12月18日,小组成员就结肠镜检查期间用于CRC筛查或息肉监测指征的CADe的两种选择中他们偏好的建议进行了投票。在19张有效选票中,13票(68.4%)投票赞成在结肠镜检查中推荐使用CADe,6名小组成员(31.6%)投票反对。因此,当前的ESGE声明为:建议:小组认为,大多数已决定接受结肠镜检查进行筛查或监测的明智患者会倾向于在结肠镜检查期间接受CADe辅助。这是因为虽然益处有限,但CADe有可能降低结直肠癌的发病率和死亡率。该建议力度较弱,因为证据有限,证据估计存在相当大的不确定性,对结直肠癌发病率和死亡率的绝对益处较小,并且CADe会给患者带来负担(更多息肉过度诊断和更多结肠镜检查监测)。